Regentis Biomaterials Ltd. has announced the publication of long-term follow-up results from its Phase II clinical trial of GelrinC®, a regenerative medicine device for cartilage repair. The study results, published in the peer-reviewed journal Cartilage, demonstrate durable cartilage regeneration at 24 months, as assessed by the MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) MRI-based quantitative measure. GelrinC is currently being evaluated in a pivotal Phase III U.S. FDA investigational device exemption $(IDE)$ study, with enrollment ongoing and over 50% of patients recruited. The Phase III study is designed to support a future premarket approval (PMA) submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-001596), on January 06, 2026, and is solely responsible for the information contained therein.